Cargando…
Appraising the European randomized study of screening for prostate cancer: what do the results mean?
The value of screening for prostate cancer has been a contentious issue within the medical literature for several decades. At the crux of the matter lies a judgment call of whether the potential benefits of screening, a reduction in prostate cancer and all-cause mortality, outweigh the limitations,...
Autor principal: | Ilic, Dragan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650457/ https://www.ncbi.nlm.nih.gov/pubmed/25432497 http://dx.doi.org/10.4103/1008-682X.142131 |
Ejemplares similares
-
To screen or not to screen: the prostate cancer dilemma
por: Stone, Nelson N, et al.
Publicado: (2015) -
Prostate cancer screening: and yet it moves!
por: Kwiatkowski, Maciej, et al.
Publicado: (2015) -
What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015) -
Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib
por: Beltran, Himisha, et al.
Publicado: (2014) -
The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2020)